Citation & Authors
Diabetes Res Clin Pract. 2025;222:112109.
ABSTRACT · RESEARCH SUMMARY
Research summary
Using a new-user, active-comparator design, the TriNetX study matched 92,090 pairs of SGLT2 and DPP-4 inhibitor users. SGLT2 inhibitors were associated with a lower risk of ovarian cancer (HR 0.758; 95% CI 0.596–0.965), with a more pronounced association in the White subgroup. Biological mechanisms and residual confounding require further investigation; this finding is not definitive evidence of cancer prevention.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
